ישראל - עברית - Ministry of Health

novartis israel ltd - lutetium (177lu) oxodotreotide - תמיסה לאינפוזיה - lutetium (177lu) oxodotreotide 370 mbq/ml - lutetium (177lu) oxodotreotide

ישראל - עברית - Ministry of Health

marshall isotope ltd, israel - lutetium (177lu) oxodotreotide - תמיסה לאינפוזיה - lutetium (177lu) oxodotreotide 370 mbq/ml - lutetium (177lu) oxodotreotide

ישראל - עברית - Ministry of Health

marshall isotope ltd, israel - lutetium (177lu) oxodotreotide - תמיסה לאינפוזיה - lutetium (177lu) oxodotreotide 370 mbq/ml - lutetium (177lu) oxodotreotide

ישראל - עברית - Ministry of Health

s.r.y. (medical services ) ltd, israel - lutetium (177lu) oxodotreotide - תמיסה לאינפוזיה - lutetium (177lu) oxodotreotide 600 mbq/ml - lutetium (177lu) oxodotreotide

ישראל - עברית - Ministry of Health

novartis israel ltd - lutetium (177lu) vipivotide tetraxetan - תמיסה להזרקה\אינפוזיה - lutetium (177lu) vipivotide tetraxetan 1000 mbq/ml - lutetium (177lu) vipivotide tetraxetan

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - octreotide as acetate - אבקה וממס להכנת תרחיף בשחרור ממושך להזרקה - octreotide as acetate 10 mg - octreotide

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - octreotide as acetate - אבקה וממס להכנת תרחיף בשחרור ממושך להזרקה - octreotide as acetate 20 mg - octreotide

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - octreotide as acetate - אבקה וממס להכנת תרחיף בשחרור ממושך להזרקה - octreotide as acetate 30 mg - octreotide

ישראל - עברית - Ministry of Health

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.1 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

ישראל - עברית - Ministry of Health

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.05 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.